Selective delivery of clinically approved tubulin binding agents through covalent conjugation to an active targeting moiety.
Sign Up to like & getrecommendations! Published in 2022 at "Current medicinal chemistry"
DOI: 10.2174/0929867329666220401105929
Abstract: The efficacy and tolerability of tubulin binding agents are hampered by their low specificity for cancer cells, like most clinically used anticancer agents. To improve specificity, tubulin binding agents have been covalently conjugated to agents… read more here.
Keywords: clinically approved; delivery clinically; tubulin binding; selective delivery ... See more keywords